Alnylam Pharmaceuticals this week announced that it has received an orphan drug designation from the US Food and Drug Administration for its subcutaneous hemophilia B treatment ALN-AT3.
The designation provides a drugmaker with, among other things, extended market exclusivity for its product, tax credits, and marketing incentives.
ALN-AT3 is expected to enter phase I testing next year.